Search research articles
Contact Us
Filters
Showing results (511-520 of 661) with videos related to
Page
of 67
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2020
Clonal Architecture of <i>EGFR</i> Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Xinghao Ai, Jiuwei Cui, Jiexia Zhang, et al.
British Journal of Cancer
|
December 23, 2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 14, 2026
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50
Mark A Socinski, Martin Reck, Luis Paz-Ares, et al.
Cancer Science
|
December 20, 2021
NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy
Hui Wang, Liliang Xia, Cheng-Cheng Yao, et al.
Annals of Translational Medicine
|
May 14, 2021
Plasma <i>EGFR</i> mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
Xiaohong Wang, Yonggang Liu, Zhiying Meng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 4, 2018
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Yi-Long Wu, Shun Lu, You Lu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 28, 2026
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer
Ross A Soo, Pablo Fernandez-Penas, Molly Li, et al.
JTO Clinical and Research Reports
|
February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
Jie Wang, Yi-Long Wu, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 12, 2018
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies
Yi-Long Wu, Victor Lee, Chong-Kin Liam, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 3, 2024
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
Byoung Chul Cho, Chao-Hua Chiu, Erminia Massarelli, et al.
Page
of 67
Search research articles
Search
Showing results (511-520 of 661) with videos related to
Sort By:
Page
of 67
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2020
Clonal Architecture of <i>EGFR</i> Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Xinghao Ai, Jiuwei Cui, Jiexia Zhang, et al.
British Journal of Cancer
|
December 23, 2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 14, 2026
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50
Mark A Socinski, Martin Reck, Luis Paz-Ares, et al.
Cancer Science
|
December 20, 2021
NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy
Hui Wang, Liliang Xia, Cheng-Cheng Yao, et al.
Annals of Translational Medicine
|
May 14, 2021
Plasma <i>EGFR</i> mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
Xiaohong Wang, Yonggang Liu, Zhiying Meng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 4, 2018
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Yi-Long Wu, Shun Lu, You Lu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 28, 2026
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer
Ross A Soo, Pablo Fernandez-Penas, Molly Li, et al.
JTO Clinical and Research Reports
|
February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
Jie Wang, Yi-Long Wu, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 12, 2018
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies
Yi-Long Wu, Victor Lee, Chong-Kin Liam, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 3, 2024
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
Byoung Chul Cho, Chao-Hua Chiu, Erminia Massarelli, et al.
Page
of 67